Profile data is unavailable for this security.
About the company
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, LBS-008 as an oral daily treatment for STGD1 and Geographic Atrophy patients. In STGD1, it is developing LBS-008 as once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4 which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009 an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
- Revenue in USD (TTM)0.00
- Net income in USD-32.61m
- Incorporated2018
- Employees20.00
- LocationBelite Bio Inc12750 High Bluff Drive Suite 475SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 246-6240
- Websitehttps://belitebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.40bn | 587.00 | -- | 0.9016 | -- | 17.55 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Pacira Biosciences Inc | 681.75m | 70.47m | 1.41bn | 711.00 | 23.41 | 1.58 | 9.74 | 2.07 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.46bn | 33.00 | -- | 9.78 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Xencor Inc | 162.18m | -133.36m | 1.47bn | 280.00 | -- | 2.39 | -- | 9.03 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.49bn | 1.60k | -- | 0.4148 | -- | 2.00 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.121 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.49bn | 20.00 | -- | 15.12 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 597.40m | -15.51m | 1.49bn | 652.00 | -- | 1.60 | 21.44 | 2.50 | -0.2843 | -0.2843 | 10.86 | 16.90 | 0.3859 | 0.922 | 4.10 | 916,259.20 | -1.00 | 4.95 | -1.51 | 6.41 | 87.17 | 88.61 | -2.60 | 12.84 | 1.49 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.52bn | 124.00 | -- | 2.29 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.52bn | 284.00 | -- | -- | -- | 36.64 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.53bn | 58.00 | 16.25 | 1.89 | 11.56 | 12.91 | 5.23 | 5.23 | 6.52 | 45.00 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 55.14m | -156.83m | 1.53bn | 154.00 | -- | 19.55 | -- | 27.80 | -1.86 | -1.86 | 0.6334 | 0.8157 | 0.3573 | -- | 4.80 | 358,058.40 | -101.63 | -40.21 | -172.85 | -47.99 | 95.71 | -- | -284.42 | -374.75 | 2.60 | -14.71 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Dynavax Technologies Corp | 236.15m | 9.22m | 1.57bn | 408.00 | 240.04 | 2.54 | 114.76 | 6.65 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Kura Oncology Inc | 0.00 | -168.09m | 1.57bn | 142.00 | -- | 3.11 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.58bn | 120.00 | -- | 3.72 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.59bn | 111.00 | -- | 3.71 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.60bn | 92.00 | -- | 2.99 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Belite Bio Inc's reporting currency: US Dollar USD
0.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fubon Asset Management Co., Ltd.as of 31 Dec 2023 | 56.51k | 0.19% |
| Uni-President Asset Management Corp.as of 31 Dec 2023 | 28.04k | 0.10% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 16.67k | 0.06% |
| Marshall Wace LLPas of 31 Mar 2024 | 10.58k | 0.04% |
| Point72 Asset Management LPas of 31 Mar 2024 | 8.70k | 0.03% |
| Geode Capital Management LLCas of 31 Mar 2024 | 6.70k | 0.02% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 6.09k | 0.02% |
| Cubist Systematic Strategies LLCas of 31 Mar 2024 | 4.79k | 0.02% |
| Virtus ETF Advisers LLCas of 31 Mar 2024 | 1.96k | 0.01% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 1.72k | 0.01% |
More ▼
Data from 31 Dec 2023 - 24 May 2024Source: FactSet Research Systems Inc.
